Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Affirm 1% Lotion
- Development stage
- Preclinical
- Lead developer
- Alsys
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Affirm 1% Lotion (PRC0028) is a topical small-molecule natural product developed by Alsys. It is designed to target S100 antimicrobial and proinflammatory proteins, which are key mediators in skin inflammation pathways. The drug is currently being investigated in preclinical studies for the prophylactic treatment of plaque psoriasis, as well as for the management of atopic dermatitis and seborrheic dermatitis. By modulating S100-mediated signaling, the therapy aims to reduce the inflammatory response characteristic of these dermatological conditions.
- Brand names
- Affirm
- Other names
- Affirm 1%Affirm Lotion 1%
Beyond the preview
Go deeper on Affirm 1% Lotion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Affirm 1% Lotion.